OTCMKTS:SBMFF

Sino Biopharmaceutical Competitors

$1.06
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.06
Now: $1.06
$1.06
50-Day Range
$0.94
MA: $1.05
$1.20
52-Week Range
$0.84
Now: $1.06
$1.92
VolumeN/A
Average Volume5,315 shs
Market Capitalization$19.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.57

Competitors

Sino Biopharmaceutical (OTCMKTS:SBMFF) Vs. ATLKY, AIQUY, SHECY, KDDIY, ESLOY, and DPSGY

Should you be buying SBMFF stock or one of its competitors? Companies in the industry of "private households" are considered alternatives and competitors to Sino Biopharmaceutical, including Atlas Copco (ATLKY), L'Air Liquide (AIQUY), Shin-Etsu Chemical (SHECY), KDDI (KDDIY), EssilorLuxottica Société anonyme (ESLOY), and Deutsche Post (DPSGY).

Atlas Copco (OTCMKTS:ATLKY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap industrial products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Institutional & Insider Ownership

0.6% of Atlas Copco shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Atlas Copco has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Atlas Copco and Sino Biopharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atlas Copco26212.18
Sino Biopharmaceutical02102.33

Profitability

This table compares Atlas Copco and Sino Biopharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atlas Copco14.71%26.53%12.69%
Sino BiopharmaceuticalN/AN/AN/A

Earnings & Valuation

This table compares Atlas Copco and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlas Copco$10.98 billion7.23$1.75 billion$1.4445.38
Sino Biopharmaceutical$3.51 billion5.68$391.67 millionN/AN/A

Atlas Copco has higher revenue and earnings than Sino Biopharmaceutical.

Summary

Atlas Copco beats Sino Biopharmaceutical on 10 of the 11 factors compared between the two stocks.

L'Air Liquide (OTCMKTS:AIQUY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap basic materials companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.2% of L'Air Liquide shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

L'Air Liquide has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for L'Air Liquide and Sino Biopharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
L'Air Liquide04502.56
Sino Biopharmaceutical02102.33

Profitability

This table compares L'Air Liquide and Sino Biopharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
L'Air LiquideN/AN/AN/A
Sino BiopharmaceuticalN/AN/AN/A

Earnings and Valuation

This table compares L'Air Liquide and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
L'Air Liquide$24.55 billion3.23$2.51 billion$1.0731.35
Sino Biopharmaceutical$3.51 billion5.68$391.67 millionN/AN/A

L'Air Liquide has higher revenue and earnings than Sino Biopharmaceutical.

Summary

L'Air Liquide beats Sino Biopharmaceutical on 6 of the 7 factors compared between the two stocks.

Shin-Etsu Chemical (OTCMKTS:SHECY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap basic materials companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.1% of Shin-Etsu Chemical shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Shin-Etsu Chemical has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Shin-Etsu Chemical and Sino Biopharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shin-Etsu Chemical00203.00
Sino Biopharmaceutical02102.33

Profitability

This table compares Shin-Etsu Chemical and Sino Biopharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shin-Etsu Chemical19.72%10.75%9.14%
Sino BiopharmaceuticalN/AN/AN/A

Earnings and Valuation

This table compares Shin-Etsu Chemical and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shin-Etsu Chemical$14.20 billion5.27$2.89 billion$1.7026.41
Sino Biopharmaceutical$3.51 billion5.68$391.67 millionN/AN/A

Shin-Etsu Chemical has higher revenue and earnings than Sino Biopharmaceutical.

Summary

Shin-Etsu Chemical beats Sino Biopharmaceutical on 9 of the 10 factors compared between the two stocks.

KDDI (OTCMKTS:KDDIY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.1% of KDDI shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

KDDI has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for KDDI and Sino Biopharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
KDDI02102.33
Sino Biopharmaceutical02102.33

Profitability

This table compares KDDI and Sino Biopharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
KDDI12.78%13.56%6.91%
Sino BiopharmaceuticalN/AN/AN/A

Earnings and Valuation

This table compares KDDI and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KDDI$48.18 billion1.52$5.89 billion$1.2712.54
Sino Biopharmaceutical$3.51 billion5.68$391.67 millionN/AN/A

KDDI has higher revenue and earnings than Sino Biopharmaceutical.

Summary

KDDI beats Sino Biopharmaceutical on 6 of the 8 factors compared between the two stocks.

EssilorLuxottica Société anonyme (OTCMKTS:ESLOY) and Sino Biopharmaceutical (OTCMKTS:SBMFF) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

0.3% of EssilorLuxottica Société anonyme shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares EssilorLuxottica Société anonyme and Sino Biopharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EssilorLuxottica Société anonymeN/AN/AN/A
Sino BiopharmaceuticalN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for EssilorLuxottica Société anonyme and Sino Biopharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
EssilorLuxottica Société anonyme14502.40
Sino Biopharmaceutical02102.33

Earnings and Valuation

This table compares EssilorLuxottica Société anonyme and Sino Biopharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EssilorLuxottica Société anonyme$19.48 billion3.67$1.21 billion$2.4633.09
Sino Biopharmaceutical$3.51 billion5.68$391.67 millionN/AN/A

EssilorLuxottica Société anonyme has higher revenue and earnings than Sino Biopharmaceutical.

Risk & Volatility

EssilorLuxottica Société anonyme has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Sino Biopharmaceutical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Summary

EssilorLuxottica Société anonyme beats Sino Biopharmaceutical on 6 of the 7 factors compared between the two stocks.

Sino Biopharmaceutical (OTCMKTS:SBMFF) and Deutsche Post (OTCMKTS:DPSGY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

0.1% of Deutsche Post shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Sino Biopharmaceutical and Deutsche Post's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sino BiopharmaceuticalN/AN/AN/A
Deutsche Post3.94%17.69%4.87%

Analyst Ratings

This is a summary of current ratings and target prices for Sino Biopharmaceutical and Deutsche Post, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sino Biopharmaceutical02102.33
Deutsche Post041002.71

Earnings & Valuation

This table compares Sino Biopharmaceutical and Deutsche Post's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sino Biopharmaceutical$3.51 billion5.68$391.67 millionN/AN/A
Deutsche Post$70.95 billion1.00$2.94 billion$2.3424.50

Deutsche Post has higher revenue and earnings than Sino Biopharmaceutical.

Volatility and Risk

Sino Biopharmaceutical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Deutsche Post has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Summary

Deutsche Post beats Sino Biopharmaceutical on 9 of the 10 factors compared between the two stocks.


Sino Biopharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Atlas Copco logo
ATLKY
Atlas Copco
1.1$65.34flat$79.37 billion$10.98 billion50.26Analyst Report
News Coverage
L'Air Liquide logo
AIQUY
L'Air Liquide
0.9$33.54flat$79.34 billion$24.55 billion31.35
Shin-Etsu Chemical logo
SHECY
Shin-Etsu Chemical
1.1$44.90flat$74.83 billion$14.20 billion27.89News Coverage
KDDI logo
KDDIY
KDDI
1.4$15.93flat$73.41 billion$48.18 billion11.80High Trading Volume
EssilorLuxottica Société anonyme logo
ESLOY
EssilorLuxottica Société anonyme
1.4$81.41flat$71.48 billion$19.48 billion33.09
Deutsche Post logo
DPSGY
Deutsche Post
1.4$57.32flat$71.02 billion$70.95 billion25.03Analyst Downgrade
High Trading Volume
News Coverage
Gap Up
Vinci logo
VCISY
Vinci
0.4$26.83flat$63.48 billion$53.83 billion0.00Analyst Report
News Coverage
Bayerische Motoren Werke Aktiengesellschaft logo
BAMXF
Bayerische Motoren Werke Aktiengesellschaft
1.4$104.50flat$62.90 billion$116.72 billion12.59Analyst Upgrade
Daikin Industries,Ltd. logo
DKILY
Daikin Industries,Ltd.
1.3$20.89flat$61.12 billion$23.46 billion38.69Analyst Upgrade
News Coverage
Pjsc Lukoil logo
LUKOY
Pjsc Lukoil
1.0$76.85flat$53.25 billion$123.17 billion32.02
DENSO logo
DNZOY
DENSO
1.0$32.57flat$51.32 billion$47.41 billion-51.69Analyst Revision
News Coverage
Oriental Land logo
OLCLY
Oriental Land
0.9$29.89flat$49.15 billion$4.27 billion-498.08
A.P. Møller - Mærsk A/S logo
AMKBY
A.P. Møller - Mærsk A/S
1.0$12.19flat$48.84 billion$38.89 billion32.08News Coverage
ITOCHU logo
ITOCY
ITOCHU
1.0$64.05flat$47.72 billion$101.26 billion11.04Analyst Downgrade
Gap Down
Jardine Matheson logo
JMHLY
Jardine Matheson
0.3$64.23flat$47.19 billion$40.92 billion0.00
HOYA logo
HOCPY
HOYA
1.1$125.61flat$46.83 billion$5.31 billion46.35News Coverage
Henkel AG & Co. KGaA logo
HENKY
Henkel AG & Co. KGaA
1.4$25.48flat$44.64 billion$22.53 billion18.87Analyst Report
Analyst Revision
News Coverage
Bank of Communications logo
BCMXY
Bank of Communications
1.2$15.01flat$44.59 billion$60.07 billion4.77
Sun Hung Kai Properties logo
SUHJY
Sun Hung Kai Properties
1.4$15.37flat$44.54 billion$10.66 billion11.73News Coverage
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München logo
MURGY
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München
0.6$31.46flat$44.08 billion$61.62 billion32.43News Coverage
The Swatch Group logo
SWGAY
The Swatch Group
0.5$15.00flat$43.76 billion$8.30 billion0.00
SMC logo
SMCAY
SMC
1.3$30.60flat$41.23 billion$4.84 billion43.10
China Shenhua Energy logo
CSUAY
China Shenhua Energy
1.3$8.21flat$40.82 billion$35.00 billion7.46
Vestas Wind Systems A/S logo
VWDRY
Vestas Wind Systems A/S
1.2$66.82flat$40.49 billion$13.61 billion75.93Analyst Downgrade
Sands China logo
SCHYY
Sands China
0.9$47.53flat$38.46 billion$8.81 billion18.94
Compass Group logo
CMPGY
Compass Group
0.8$21.53flat$38.41 billion$25.75 billion89.71Analyst Upgrade
Flutter Entertainment logo
PDYPY
Flutter Entertainment
0.4$106.15flat$37.17 billion$2.73 billion55.58
Sandvik AB (publ) logo
SDVKY
Sandvik AB (publ)
0.8$28.62flat$35.90 billion$10.92 billion54.00Analyst Report
Kuehne + Nagel International logo
KHNGY
Kuehne + Nagel International
0.9$59.64flat$35.70 billion$21.23 billion44.18
Seven & i logo
SVNDY
Seven & i
1.6$19.78flat$34.99 billion$61.13 billion21.04Gap Down
H & M Hennes & Mauritz AB (publ) logo
HNNMY
H & M Hennes & Mauritz AB (publ)
0.7$4.65flat$33.96 billion$24.63 billion155.00Upcoming Earnings
Analyst Report
Japan Tobacco logo
JAPAY
Japan Tobacco
1.2$9.45flat$33.52 billion$19.96 billion12.43
Experian logo
EXPGY
Experian
1.1$36.46flat$33.45 billion$5.18 billion35.75High Trading Volume
News Coverage
Techtronic Industries logo
TTNDY
Techtronic Industries
0.2$89.93flat$32.97 billion$7.67 billion0.00News Coverage
ASSA ABLOY AB (publ) logo
ASAZY
ASSA ABLOY AB (publ)
1.2$15.16flat$31.99 billion$9.95 billion36.98High Trading Volume
Amadeus IT Group logo
AMADY
Amadeus IT Group
0.5$70.47flat$31.75 billion$6.25 billion-242.99News Coverage
CK Hutchison logo
CKHUY
CK Hutchison
0.7$8.07flat$31.12 billion$38.34 billion0.00
Swire Pacific logo
SWRAY
Swire Pacific
1.6$7.98flat$31.00 billion$10.93 billion3.18News Coverage
Fujitsu logo
FJTSY
Fujitsu
0.9$30.59flat$31.00 billion$35.49 billion23.17Gap Up
Ashtead Group logo
ASHTY
Ashtead Group
1.2$256.00flat$28.76 billion$5.84 billion35.36News Coverage
Gap Up
Associated British Foods logo
ASBFY
Associated British Foods
0.9$34.11flat$27.00 billion$18.00 billion32.48Analyst Report
News Coverage
Sampo Oyj logo
SAXPY
Sampo Oyj
0.8$24.07flat$26.96 billion$12.62 billion18.80Analyst Report
News Coverage
Zalando logo
ZLNDY
Zalando
0.4$52.13flat$26.61 billion$7.26 billion236.97Analyst Upgrade
News Coverage
Compagnie Générale des Établissements Michelin Société en commandite par actions logo
MGDDY
Compagnie Générale des Établissements Michelin Société en commandite par actions
1.5$29.77flat$26.55 billion$27.03 billion13.72Analyst Downgrade
News Coverage
Wilmar International logo
WLMIY
Wilmar International
0.7$40.85flat$25.80 billion$42.64 billion20.02
Sunny Optical Technology (Group) logo
SNPTF
Sunny Optical Technology (Group)
0.5$22.95flat$25.17 billion$5.48 billion0.00News Coverage
Unicharm logo
UNICY
Unicharm
0.9$8.36flat$24.83 billion$6.55 billion64.31Analyst Upgrade
Analyst Revision
Gap Down
UniCredit logo
UNCFF
UniCredit
1.2$10.62flat$23.79 billion$25.52 billion11.06
Kerry Group logo
KRYAY
Kerry Group
1.2$134.26flat$23.73 billion$8.11 billion30.44News Coverage
BAE Systems logo
BAESY
BAE Systems
1.4$28.57flat$23.00 billion$22.52 billion14.00Dividend Increase
Analyst Downgrade
News Coverage
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.